phrykt

Alx Oncology Holdings Inc (ALXO): who owns it and who trades it

As of Nov 16, 2026, ALXO insiders reported 7 open-market sales worth $42.6K and 1 purchase worth $5M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jason Lettmann (CEO), with $31K. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Alx Oncology

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ALXO

94 funds and institutions reported ALXO shares worth $220M at the end of Q2 2026, about 81% of the company. The largest holder is Ra Capital Management, L.P. with 9.9%.

Funds and institutions (13F) 81%Everyone else 19%

10 largest owners, by share of the company

Ra Capital Management, L.P.9.9%
VenBio Partners LLC9.8%
BlackRock, Inc.5.6%
Redmile Group, LLC5.6%
Blackstone Inc.5.0%
Driehaus Capital Management LLC4.6%
Silverarc Capital Management, LLC4.4%
TCG Crossover Management, LLC4.3%
Vanguard Capital Management LLC3.8%
Vivo Capital, LLC2.4%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Ra Capital Management, L.P.13.01M9.89%$26.9MNo change
VenBio Partners LLC12.88M9.79%$26.7MNo change
BlackRock, Inc.7.40M5.62%$15.3M+1552%
Redmile Group, LLC7.39M5.62%$15.3M-7%
Blackstone Inc.6.59M5.01%$13.6M+13%
Driehaus Capital Management LLC6.03M4.58%$12.5M+5%
Silverarc Capital Management, LLC5.74M4.37%$11.9MNew
TCG Crossover Management, LLC5.66M4.30%$11.7M-57%
Vanguard Capital Management LLC4.97M3.78%$10.3M+19%
Vivo Capital, LLC3.18M2.42%$6.6MNo change
Marshall Wace, LLP3.07M2.33%$6.4M-18%
5AM Venture Management, LLC3.06M2.32%$6.3MNo change
Almitas Capital LLC2.94M2.23%$6.1M-7%
Orbimed Advisors LLC2.87M2.18%$5.9MNo change
Geode Capital Management, LLC2.79M2.12%$5.8M+465%
Two Sigma Investments, LP2.18M1.66%$4.5M+37%
Millennium Management LLC1.54M1.17%$3.2M-22%
Nantahala Capital Management, LLC1.50M1.14%$3.1MNew
State Street Corp1.50M1.14%$3.1M+752%
Acadian Asset Management LLC1.31M1.00%$2.7M+19%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ALXO insiders reported $5M of open-market purchases and $42.6K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$5M
1 trades, 1 people
Sales, 12 months
$42.6K
7 trades, 2 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Aug 17, 2026
Filed Aug 18, 2026

Purchases and sales by month

$5M$5MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Aug 17, 2026Jason LettmannCEOSale2,230$1.93$4.3KForm 4
Aug 17, 2026Shelly WongVice presidentSale573$1.93$1.1KForm 4
Jul 1, 2026Shelly WongVice presidentSale1,404$2.04$2.9KForm 4
Mar 19, 2026Jason LettmannCEOSale12,311$2.17$26.7KForm 4
Mar 19, 2026Shelly PintoVice presidentSale903$2.17$2KForm 4
Feb 18, 2026Shelly PintoVice presidentSale565$2.27$1.3KForm 4
Feb 2, 2026Corey S GoodmanDirectorPurchase3.18M$1.57$5MForm 4
Jan 6, 2026Shelly PintoVice presidentSale3,925$1.11$4.4KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Corey S GoodmanDirector, 10% owner$5M–Feb 2, 2026
Jason LettmannCHIEF EXECUTIVE OFFICER, Director–$31KAug 17, 2026
Shelly PintoSVP, FINANCE AND CAO–$11.6KAug 17, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ALXO short interest

Low short interest. 4.5% of ALXO shares are sold short: about 1 share in 22. Over the last 12 reports the number of shares short went up 347%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 6.17M ALXO shares were sold short, 4.5% of the shares outstanding, up 3.2% from the report before. At the average daily volume of 1.39M shares, buying them all back would take about 4.4 trading days (days to cover).

Shares short, % of all shares

4.46%May 15Oct 306.36%

Days to cover

4.4May 15Oct 3015.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20266.17M4.46%+3%1.39M4.4
Oct 15, 20265.98M4.32%+5%1.65M3.6
Sep 30, 20265.67M4.10%-10%1.50M3.8
Sep 15, 20266.27M4.54%-11%805,3527.8
Aug 31, 20267.06M5.11%-7%575,10512.3
Aug 14, 20267.61M5.51%-1%1.57M4.8
Jul 31, 20267.72M5.58%+3%581,14613.3
Jul 15, 20267.46M5.67%+18%1.13M6.6
Jun 30, 20266.32M4.80%+144%3.06M2.1
Jun 15, 20262.59M1.97%+52%980,8632.6
May 29, 20261.71M1.30%+24%1.28M1.3
May 15, 20261.38M1.05%-37%713,7751.9

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Alx Oncology company events

Alx Oncology filed 11 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Oct 15, 2026.

  1. Oct 15, 2026AgreementALX Oncology Holdings Inc. entered into separate privately-negotiated exchange agreements (each, an “Exchange Agreement”), with certain stockholders of the Company, pursuant to which the Stockholders agreed to surrender an aggregate of 13,353,384 shares of the Company’s common stock, par value… Filing
  2. Aug 6, 2026ResultsReleased financial results. Filing
  3. Jun 30, 2026LeadershipCorey Goodman, Ph.D. informed ALX Oncology Holdings Inc. of his resignation as Chairman of the Company’s board of directors and as a member of the Board, and from all committees thereof, to be effective as of the close of business on June 29, 2026. Filing
  4. Jun 26, 2026AgreementALX Oncology Holdings Inc., a Delaware corporation, entered into a loan and security agreement among HSBC Ventures USA Inc., as lender, ALX Oncology Inc., a Delaware corporation, as borrower, and the Company and ALX Oncology Limited, as guarantors. Filing
  5. Jun 11, 2026VoteReported shareholder vote results. Filing
  6. May 8, 2026ResultsReleased financial results. Filing
  7. Apr 13, 2026LeadershipThe Board of Directors of ALX Oncology Holdings Inc. appointed Jeff Knight as Chief Development and Operating Officer. Filing
  8. Feb 27, 2026ResultsReleased financial results. Filing
  9. Jan 30, 2026AgreementALX Oncology Holdings Inc. entered into an underwriting agreement with Piper Sandler & Co., UBS Securities LLC and Wells Fargo Securities, LLC as representatives of the several underwriters named therein, relating to the issuance and sale of 76,979,112 shares of the Company’s common stock, par… Filing
  10. Jan 30, 2026AnnouncementALX Oncology Holdings Inc. issued a press release announcing new data from a Phase 1b/2 clinical trial evaluating the Company’s investigational CD47-inhibitor evorpacept in combination with Jazz Pharmaceuticals’ ZIIHERA® (zanidatamab-hrii) in heavily pretreated patients with metastatic breast cancer. Filing
  11. Jan 21, 2026LeadershipThe Board of Directors of ALX Oncology Holdings Inc. amended the 2025 Inducement Equity Incentive Plan to increase the number of shares reserved for issuance under the Inducement Plan. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Alx Oncology financials

Famous investors that hold ALXO

4 of the 50 well-known investors we track reported holding ALXO in their latest 13F filing. The largest position is Israel Englander's, worth $3.3M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 20262.36M$3.3M0.0%+53%
Jim Simons · Renaissance TechnologiesQ3 2026459,013$638K0.0%-24%
Ken Griffin · Citadel AdvisorsQ3 2026166,741$232K0.0%New
Steve Cohen · Point72 Asset ManagementQ3 202636,134$50.2K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named ALXO in the last 120 days.

FiledHolderFormStake
Oct 16, 2026venBio Global Strategic Fund, L.P.13D/A3.3%
Oct 16, 2026venBio Global Strategic Fund, L.P.13D/A3.3%

Questions about Alx Oncology Holdings Inc (ALXO) stock

Who owns the most ALXO stock?

The largest reported owner of Alx Oncology Holdings Inc (ALXO) is Ra Capital Management, L.P., with 9.9% of the company. In total, 94 funds and institutions reported holding ALXO at the end of Q2 2026, together about 81% of the shares. See the largest owners.

Are ALXO insiders buying or selling?

In the last 12 months, ALXO insiders reported 1 open-market purchase worth $5M and 7 sales worth $42.6K. The latest trade was on Aug 17, 2026. See every trade.

What is the short interest in ALXO?

As of Oct 30, 2026, 6.17M ALXO shares were sold short, 4.5% of the shares outstanding, up 3.2% from the report before. At the average daily volume of 1.39M shares, buying them all back would take about 4.4 trading days (days to cover). See the history.

Which famous investors hold ALXO?

4 of the 50 well-known investors we track reported ALXO in their latest 13F filing, including Israel Englander, Jim Simons, Ken Griffin. The largest position is worth $3.3M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.